Article
Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome.
Thrombosis and haemostasis - 1 Jan 2016
Collet Jean-Philippe, Kerneis Mathieu, Hulot Jean-Sébastien, O'Connor Stephen A, Silvain Johanne, Mansencal Nicolas, Brugier Delphine, Abtan Jérémie, Barthélémy Olivier, Vignalou Jean-Baptiste, Payot Laurent, Rousseau Hélène, Vicaut Eric, Montalescot Gilles
Abstract excerpt
Our aim was to demonstrate that the sequential use of the Verigene® rapid CYP2C19 test for genetic profiling and the VerifyNowTM bedside test for platelet function measurement in ACS patients may optimise P2Y12 inhibition. "Rapid" (CYP2C19*1/*1 or CYP2C19*17 carriers, n=211) and "slow" metabolisers (CYP2C19*2 carriers, n=58) were first put on clopidogrel and prasugrel for ≥ 2 weeks, respectively. Patients with...
Topics
Join the communities discussing this publication.